Related Experiment Video
Updated: Mar 21, 2026

08:50
Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
7.6K
RIPK3-a predictive marker for personalized immunotherapy?
1Institute of Virology, Saarland University , Homburg/Saar, Germany.
Oncoimmunology
|May 4, 2016
Abstract:
Cancer immunotherapy is an attractive therapeutic option but it is currently unclear which patient may benefit from such approaches. Using the model of cervical cancer, we have demonstrated that PolyIC-driven immunogenicity strictly depends on the necroptosis regulator RIPK3 in the neoplastic cells. This proposes RIPK3 as a novel predictive marker for personalization of cancer immunotherapy.

